VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Neuroscientist Patrik Verstreken of VIB (Flanders Institute for Biotechnology) and KU Leuven has shown for the first time that dysfunctional mitochondria in brain cells can lead to learning disabilities. The link between dysfunctional mitochondria and Parkinson's disease is known, but this new research shows that it is also present in other brain disorders. read more
Galapagos NV (Euronext: GLPG) announced today that the Company will present three posters on selective JAK1 inhibitor GLPG0634 at the EULAR Annual European Congress of Rheumatology, which will take place from 12-15 June 2013 in Madrid, Spain. The abstracts are now available online at www.eular.org. Information going beyond that contained in the abstracts is under embargo until 00:01h of the opening day of the EULAR Congress, Wednesday 12 June. read more
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced the publication of the clinical utility of epigenetic diagnosis to improve the management of prostate cancer. The results were published in the Journal of Oncopathology 2013;1:29-32. read more
An international consortium – including scientists from VIB, KU Leuven and UZ Leuven – has identified more than 80 regions in our DNA that increase a person’s risk of developing breast, prostate and ovarian cancer. It is the first time that this type of study has been performed on such a large scale. Diether Lambrechts (VIB/KU Leuven) coordinated the Belgian part of the study into risk factors for breast cancer and ovarian cancer. read more
General anesthetic result in a loss of consciousness and insensitivity to pain, apparently in the same manner in all animals, from invertebrates to humans. However, the molecular mechanisms involved are not yet known. Recent research by Patrik Verstreken (VIB/KU Leuven) about the role of the lipid PIP3 in brain cells of fruit flies could provide more insight into this. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, and collaborator Ghent University, today announced the results from a large, epigenetic next generation sequencing based study that establishes a sensitive and cost-effective industry standard for genome-wide DNA methylation profiling. The results were published in the March 15 PLOS One Volume 8, Issue 3 (e59068). This study is an early result of the NXTGNT Center in Pharmaco (Epi)genomics, a joint collaboration between MDxHealth and the Ghent University first announced in November 2012. read more
Uit onderzoek van Gent-wetenschapper Ophélia Maertens aan Harvard Medical School, blijkt dat het eiwit ‘neurofibromine’ (NF1) samenwerkt met het BRAF-gen bij het ontstaan van kwaadaardig melanoom. Dit soort melanomen zou doeltreffend behandeld kunnen worden met een combinatie van twee nieuwe therapieën. read more
Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2012, which have been prepared in accordance with IFRS as adopted by the European Union. read more
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform. read more
